Literature DB >> 3966120

Shoulder arthrography: comparison of morbidity after use of various contrast media.

F M Hall, R P Goldberg, G Wyshak, R F Kilcoyne.   

Abstract

This prospective study compares immediate and delayed patient discomfort in 177 patients following shoulder arthrography using intraarticular combinations of metrizamide, meglumine/sodium diatrizoate, meglumine diatrizoate, lidocaine, epinephrine, and air. Patients receiving conventional ionic monomeric positive contrast media had a 60% (90/150) incidence of moderate or severe delayed exacerbation of their baseline symptoms; only 14% (3/21) of patients receiving metrizamide, a nonionic contrast medium, had similar levels of postprocedural discomfort. Morbidity was somewhat diminished with the use of double-contrast (45%, 34/75) rather than single-contrast (75%, 56/75) examinations, and with avoidance of sodium-containing contrast agents or epinephrine. Nonionic or monovalent polymeric contrast media, despite their present high cost, may be the agents of choice if single-contrast arthrography is performed in joints (such as the shoulder, hip, and temporomandibular) associated with a high incidence of post-procedural pain.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3966120     DOI: 10.1148/radiology.154.2.3966120

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Direct shoulder magnetic resonance arthrography for superior labral anterior-to-posterior (SLAP) and Bankart lesions: investigation into the appropriate dose and level of local anesthesia.

Authors:  Sun Hwa Lee; Seong Jong Yun; Hyeon Hwan Jo; Dong Hyeon Kim; Jae Gwang Song; Yong Sung Park
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

2.  Preliminary observations on the effects of meloxicam in a new model for acute intra-articular inflammation in dogs.

Authors:  H Van Bree; C Justus; J F Quirke
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.